Breakthrough in Kidney Transplant Monitoring: PRISM MarketView Spotlights Oncocyte’s VitaGraft Study
New York, June 3, 2024—Oncocyte’s (Nasdaq: OCX) VitaGraft Kidney™ diagnostic test for transplant monitoring has shown promising results in a Phase 2 clinical trial, published

